签约拿下多个药品项目，嘉应制药加速推进创新发展

Group 1 - The core viewpoint of the articles highlights that under the backdrop of increasing health demands from residents, traditional Chinese medicine companies are expanding their development space through innovative research and development [1][2] - Recently, Jia Ying Pharmaceutical signed research and development cooperation agreements with several institutions, aiming to deepen involvement in multiple innovative and generic drug projects [1] - The cooperation includes the technology transfer of the chemical drug Bilastine tablets and the joint development of high-end generic drug projects JH003 and JH004, targeting areas such as hyperuricemia/gout and heart failure [1] Group 2 - This collaboration is a significant implementation of Jia Ying Pharmaceutical's "4+4" strategy, focusing on new drug research and new product introduction as core strategic elements [2] - The company aims to build a product matrix that integrates traditional Chinese medicine innovation with the field of chemical drug generics, leveraging its "Keya" brand advantages in traditional Chinese medicine [2] - Future plans include enhancing the penetration of core categories in hospitals, OTC, and new retail channels, transitioning the "Keya" brand from product output to health solution provision [2]